Evidence map›Paper›PMID 29383677›Full record

ArticleEndocrine2018

Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study.

A Albani, F Ferraù, A Ciresi, R Pivonello, C Scaroni, D Iacuaniello, M Zilio, V Guarnotta, A Alibrandi, E Messina and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Pasireotide-a novel somatostatin receptor ligand after 20 years of use.Reviews in endocrine & metabolic disorders · 2022
    Review
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

A AlbaniDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
F FerraùDepartment of Human Pathology of Adulthood and Childhood 'G. Barresi', University of Messina, Messina, Italy. francesco.ferrau1@gmail.com.ORCID http://orcid.org/0000-0002-7472-6598
A CiresiSection of Endocrinology, Diabetology and Metabolism, DIBIMIS, University of Palermo, Palermo, Italy.
R PivonelloDepartment of Clinical Medicine and Surgery, Endocrinology Unit, University of Naples Federico II, Naples, Italy.
C ScaroniDepartment of Medicine (DIMED), Endocrinology Unit, University-Hospital of Padua, Padova, Italy.
D IacuanielloDepartment of Clinical Medicine and Surgery, Endocrinology Unit, University of Naples Federico II, Naples, Italy.
M ZilioDepartment of Medicine (DIMED), Endocrinology Unit, University-Hospital of Padua, Padova, Italy.
V GuarnottaSection of Endocrinology, Diabetology and Metabolism, DIBIMIS, University of Palermo, Palermo, Italy.
A AlibrandiDepartment of Economics, University of Messina, Messina, Italy.
E MessinaUnit of Endocrinology, University Hospital 'G. Martino', Messina, Italy.
M BoscaroDepartment of Medicine (DIMED), Endocrinology Unit, University-Hospital of Padua, Padova, Italy.
C GiordanoSection of Endocrinology, Diabetology and Metabolism, DIBIMIS, University of Palermo, Palermo, Italy.
A ColaoDepartment of Clinical Medicine and Surgery, Endocrinology Unit, University of Naples Federico II, Naples, Italy.
S CannavoDepartment of Human Pathology of Adulthood and Childhood 'G. Barresi', University of Messina, Messina, Italy.
University of Messina · ITUniversity of Naples Federico II · ITUniversity of Padua · ITUniversity of Palermo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePatients with Cushing's disease (CD) experience metabolic alterations leading to increased cardiovascular mortality. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue dysfunction (ATD) and of the related cardiometabolic risk. We aimed to evaluate the impact of 12-month pasireotide treatment on cardiometabolic risk in CD patients.

methodsThis is a multicentre, prospective, and observational study. Sixteen CD patients, referred to the Endocrine Units of the University Hospitals of Messina, Napoli, Padova, and Palermo (Italy), successfully treated with pasireotide for 12 month have been enrolled. In all patients, we assessed anthropometric, clinical, and biochemical parameters and calculated VAI, ATD severity, Framingham, and atherosclerotic cardiovascular disease (ASCVD) risk scores, before and after 6 and 12 months of treatment with pasireotide (1200-1800 mcg/daily).

resultsBefore starting pasireotide treatment, ATD was present in 7/16 patients (mild in 2/16, moderate in 3/16, and severe 2/16). After 12 months of treatment: (i) 24h-urinary free cortisol levels (p = 0.003), BMI (p < 0.001), waist circumference (p = 0.001), LDL-cholesterol (p = 0.033), total-cholesterol (p = 0.032), triglycerides (p = 0.030), VAI (p = 0.015), and ATD severity (p = 0.026) were significantly decreased as compared to baseline; (ii) ATD was present in only 1/16 patients; (iii) prevalence of diabetes mellitus (p = 0.015) and HbA1c levels (p = 0.001) were significantly increased as compared to baseline; (iv) Framingham and ASCVD risk scores were not significantly different from pre-treatment values.

conclusionsTwelve-month pasireotide treatment significantly reduces VAI and ATD in CD patients. These positive effects on cardiometabolic risk occur despite no change in Framingham and ASCVD risk scores and the increase in the prevalence of diabetes mellitus.

Indexed as

AdiposityAdultAtherosclerosisFemaleHeart DiseasesHumansIntra-Abdominal FatItalyLongitudinal StudiesMaleMetabolic DiseasesMiddle AgedObesity, AbdominalPituitary ACTH HypersecretionProspective StudiesRisk FactorspasireotideSomatostatinCardiometabolic riskCushing’s diseaseHypercortisolismPasireotideVisceral adiposity index

Identifiers

PMID29383677
OpenAlexW2792422034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.